Thrombolytic drugs are medications that dissolve dangerous blood clots blocking arteries or veins. Often called “clot busters,” they work by activating your body’s own clot-dissolving system and are used in emergencies like heart attacks, strokes, and severe pulmonary embolisms where restoring blood flow quickly can mean the difference between recovery and permanent damage.
How Thrombolytics Dissolve Clots
Your blood naturally contains an inactive protein called plasminogen. When a clot forms, plasminogen accumulates within the clot’s mesh-like structure. Thrombolytic drugs act as plasminogen activators: they convert this inactive protein into plasmin, an enzyme that chews through the fibrin threads holding a clot together. As plasmin breaks down fibrin, the clot disintegrates and blood flow resumes.
Different thrombolytics accomplish this conversion in slightly different ways. Some bind directly to plasminogen and cleave it into plasmin. Others form a complex with circulating plasminogen first, which then converts additional plasminogen molecules in a chain reaction. The newer agents are designed to be more “fibrin-specific,” meaning they preferentially activate plasminogen that’s already embedded in the clot rather than activating plasminogen floating freely in the bloodstream. This specificity matters because widespread plasmin activation can break down clotting factors throughout the body and increase bleeding risk.
Types of Thrombolytic Drugs
The two most important thrombolytics in current practice are alteplase and tenecteplase. Alteplase was for decades the only thrombolytic approved for treating acute ischemic stroke in the United States. In March 2025, the FDA granted approval to tenecteplase for stroke as well, marking a significant shift in treatment.
Tenecteplase is a bioengineered variant of alteplase with several practical advantages. It has a longer half-life, greater fibrin specificity, and more resistance to the body’s natural inhibitors. The biggest difference for patients is how it’s given: tenecteplase is a single injection delivered over about five seconds, while alteplase requires an initial dose followed by a continuous one-hour infusion. That simplicity speeds up treatment, especially when patients need to be transferred between hospitals. Multiple large trials have confirmed that tenecteplase performs comparably to alteplase for stroke outcomes at 90 days, and its easier administration is pushing it toward becoming the preferred option.
Older thrombolytics like streptokinase and urokinase are still used in some settings around the world, particularly for heart attacks and clotted catheters, though they’ve largely been replaced by the newer fibrin-specific agents in countries where those are available.
When Thrombolytics Are Used
Ischemic Stroke
In stroke, a clot blocks blood flow to part of the brain, and every minute without treatment means more brain tissue dies. Thrombolytics are most effective when given within three hours of symptom onset, with strong evidence supporting their safety and efficacy in that window. Treatment can extend to 4.5 hours, though the benefit diminishes with each passing hour. For patients who wake up with stroke symptoms or don’t know when their symptoms started, specialized brain imaging can identify those who may still benefit from treatment within 4.5 hours of when the stroke was first noticed.
Patients with mild stroke symptoms that aren’t disabling (like slight numbness that doesn’t impair function) generally aren’t treated with thrombolytics, since the bleeding risk outweighs the expected benefit.
Heart Attack
During a heart attack caused by a completely blocked coronary artery, the preferred treatment is an emergency procedure to physically open the artery with a catheter. But when that procedure isn’t available quickly enough, thrombolytics serve as the alternative. Administering them within six hours of symptom onset prevents roughly 30 early deaths per 1,000 treated patients, with the greatest benefit in the first few hours.
Pulmonary Embolism
A pulmonary embolism occurs when a clot travels to the lungs and blocks blood flow. Most cases are managed with blood thinners alone, but thrombolytics become necessary in high-risk cases where the clot is large enough to cause shock or dangerously low blood pressure. These severe cases account for fewer than 5% of all pulmonary embolisms. For patients in an intermediate-risk category, those who aren’t in shock but show signs of strain on the right side of the heart, worsening oxygen levels, or large clot burden, thrombolytics may be considered if the bleeding risk is low.
Risks and Side Effects
The most serious risk of thrombolytic therapy is bleeding, particularly bleeding in the brain. In stroke patients treated with alteplase, symptomatic brain hemorrhage occurs in roughly 2 to 3% of cases, though rates reported across studies range from 2 to 8% depending on how the complication is defined. An additional 8% or so experience smaller, asymptomatic bleeds detected on follow-up imaging that don’t cause new symptoms.
Bleeding can also occur at other sites: the gums, IV insertion points, the gastrointestinal tract, or the urinary tract. Because the drug activates the body’s clot-dissolving system, any area where clotting is actively happening becomes vulnerable. Before and during treatment, blood tests monitor clotting function and blood counts to catch signs of excessive bleeding early. If arterial access is needed during an infusion, clinicians use compressible vessels and apply firm pressure for at least 30 minutes afterward.
Who Cannot Receive Thrombolytics
Because these drugs powerfully inhibit clotting, several conditions make their use too dangerous. The absolute contraindications include:
- Active bleeding in the brain. Any type of intracranial hemorrhage found on a CT scan rules out treatment.
- History of brain hemorrhage. A prior bleed in the brain at any point in a patient’s life is a disqualifying factor.
- Uncontrolled high blood pressure. Readings above 185/110 mmHg must be brought down before treatment can begin.
- Recent head trauma or stroke. Significant head injury or a previous stroke within the past three months.
- Low platelet count or active clotting disorders. Conditions that already impair the blood’s ability to clot make thrombolytics far too risky.
- Current use of blood thinners. Patients on anticoagulants with elevated clotting times cannot safely receive thrombolytics.
- Brain tumors, aneurysms, or vascular malformations. These structural abnormalities carry a high risk of catastrophic bleeding.
Before any thrombolytic is administered, a non-contrast CT scan of the brain is performed to rule out bleeding, and blood pressure is checked and controlled if elevated. These steps happen rapidly, often within minutes, because the treatment window is narrow and the benefit drops with every delay.
What Treatment Looks Like
If you’re receiving tenecteplase, the experience is straightforward: a single injection into a vein, delivered in seconds. With alteplase, you’ll receive a smaller initial dose as a quick injection followed by the remaining dose through a continuous IV drip over one hour. During and after the infusion, your blood pressure, neurological status, and vital signs are monitored frequently. Any sudden headache, confusion, or new weakness gets immediate attention because it could signal a complication.
Thrombolytics are strictly emergency medications given in hospitals, typically in emergency departments or intensive care settings. They are not ongoing treatments. After the clot-dissolving drug does its work, the focus shifts to preventing new clots from forming, usually with blood thinners started after a waiting period to ensure there’s no active bleeding.